checkAd

     133  0 Kommentare NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress - Seite 3

    Company Contact
    Matthew Philippe
    P: 1 917-882-7512
    matthew.philippe@newamsterdampharma.com

    Media Contact
    Spectrum Science on behalf of NewAmsterdam
    Jenn Gordon
    P: 1 202-957-7795
    jgordon@spectrumscience.com

    Lesen Sie auch

    Investor Contact
    Stern Investor Relations on behalf of NewAmsterdam
    Hannah Deresiewicz
    P: 1 212-362-1200
    hannah.deresiewicz@sternir.com



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress - Seite 3 NAARDEN, the Netherlands and MIAMI, March 25, 2024 (GLOBE NEWSWIRE) - NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for …